A Phase 2 interventional study of Carboplatin and Topotecan in Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome and Atypical Chronic Myeloid Leukemia, sponsored by National Cancer Institute (NCI). Active, not recruiting at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-23.
Sponsored by National Cancer Institute (NCI) · Phase 2, Interventional, and Treatment
This phase II trial studies how well topotecan hydrochloride and carboplatin with or without veliparib work in treating patients with myeloproliferative disorders that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced), and acute myeloid leukemia or chronic myelomonocytic leukemia. Drugs used in chemotherapy, such as topotecan hydrochloride and carboplatin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Veliparib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving topotecan hydrochloride, carboplatin, and veliparib may work better in treating patients with myeloproliferative disorders and acute myeloid leukemia or chronic myelomonocytic leukemia compared to topotecan hydrochloride and carboplatin alone.
PRIMARY OBJECTIVE:
I. To estimate and compare the complete response/complete response with incomplete recovery (CR/CRi) rate of induction therapy with topotecan hydrochloride (topotecan)/carboplatin (T/C) with or without veliparib (V) in myeloproliferative disorder associated leukemias and chronic myelomonocytic leukemia (CMML).
SECONDARY OBJECTIVES:
I. To evaluate and compare the toxicities of T/C/V versus (vs.) T/C. II. To compare the 2-year disease-free survival (DFS) and overall survival (OS) in response to T/C/V vs. T/C.
III. To detect and compare the presence of minimal residual disease (MRD) remaining after T/C/V vs. T/C.
IV. Evaluate predictive biomarkers of response via assessment of pretreatment impaired homologous recombination via assessment of:
IVa. Next generation sequencing (NGS) panel for genes mutated in myeloid malignancies done as standard of care per institution.
IVb. Functional impairment of deoxyribonucleic acid (DNA) damage response via assessment of pretreatment samples for radiation-induced RAD51 foci.
IVc. Topotecan-induced stabilization of topoisomerase I-DNA covalent complexes, which has recently been observed to be a critical predictor of response to combination of a topoisomerase I poison and PARP inhibitor in xenografts.
V. To evaluate veliparib exposure and contribution to response (efficacy and toxicity).
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive veliparib orally (PO) twice daily (BID) on days 1-21 and topotecan hydrochloride intravenously (IV) continuously over 24 hours and carboplatin IV continuously over 24 hours on days 3-7. Treatment repeats every 28-63 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
ARM B: Patients receive topotecan hydrochloride IV continuously over 24 hours and carboplatin IV continuously over 24 hours on days 1-5. Treatment repeats every 28-63 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for a minimum of 30 days, or longer.
3,667 studies on the registry are indexed under Leukemia, Myeloid, Acute; 816 are open to participants now.
This study's enrollment of 25 is below the median of 40 across 3,005 interventional studies indexed under Leukemia, Myeloid, Acute.
Browse Leukemia, Myeloid, Acute studies →National Cancer Institute (NCI) is the lead sponsor of 3,556 studies on the registry; 336 are open to participants now.
Of its 411 completed or terminated interventional studies of FDA-regulated products, 373 (91%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Accelerated phase myeloproliferative disorders per Zeider et al with two or fewer prior therapies
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive veliparib PO BID on days 1-21 and topotecan hydrochloride IV continuously over 24 hours and carboplatin IV continuously over 24 hours on days 3-7. Treatment repeats every 28-63 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
Drug: Carboplatin · Drug: Topotecan · Drug: Topotecan Hydrochloride · Drug: Veliparib
Patients receive topotecan hydrochloride IV continuously over 24 hours and carboplatin IV continuously over 24 hours on days 1-5. Treatment repeats every 28-63 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
Drug: Carboplatin · Drug: Topotecan · Drug: Topotecan Hydrochloride
Given IV
Also known as: Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo
Given IV
Also known as: Hycamptamine, Topotecan Lactone
Given IV
Also known as: Evotopin, Hycamptamine, Hycamtin, Nogitecan Hydrochloride, Potactasol, SKF S 104864 A, SKF S-104864-A, SKF S104864A, Topotec, Topotecan HCl, topotecan hydrochloride (oral)
Given PO
Also known as: ABT 888, ABT-888, ABT888, PARP-1 inhibitor ABT-888
Number of Participants With a Response
Based on published standards for acute leukemias, Complete Response (CR) means less than 5% leukemic blasts in the bone marrow, no blasts in the blood, no longer presence of cytogenetic abnormalities, no longer presence of extramedullary disease, with or without absolute neutrophil count or platelet count recovery; Partial Remission (PR) includes the criteria for Complete Remission except there are 5-25% leukemic blasts in the bone marrow and there is absolute neutrophil count and platelet count recovery; Hematologic Improvement (HI) means the disease has not gotten worse and there is at least a 20% decrease in the leukemic blasts in the bone marrow and/or a decrease in leukemia symptoms. Response = CR, PR, or HI.
Time frame: Up to 7 months
The Highest Grade Adverse Event Experienced
Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.
Time frame: Up to 7 months
Number of Participants Without Disease at Study Completion
Study completion was either death or completion of all protocol-specified activities, whichever came first. Participants who came off study due to disease-related death were counted as having disease.
Time frame: Up to 7 months
Duration of Disease-free Survival
Disease-free survival is defined as participants who are still alive and without disease at study completion. Study completion was either death or completion of all protocol-specified activities, whichever came first.
Time frame: Up to 7 months
Number of Participants Still Alive at Study Completion
Study completion was either death or completion of all protocol-specified activities, whichever came first.
Time frame: Up to 7 months
Duration of Overall Survival at the Time of Study Completion
Study completion was either death or completion of all protocol-specified activities, whichever came first. Duration was measured from the date of registration to the participant's study completion date.
Time frame: Up to 7 months
Number of Participants With Minimal Residual Disease (MRD) After Treatment
Minimal residual disease (MRD) refers to a small number of leukemic cells that remain after treatment.
Time frame: Up to 7 months
Distribution of Mutations in Deoxyribonucleic Acid (DNA) Repair Defects Via Assessment in Leukemia Mutation Panel
Will be summarized using descriptive statistics. The association response will be described with appropriate tests for continuously measured biomarkers (t tests, Wilcoxon rank sum tests) and categorical biomarkers (Fisher's exact test). Descriptive analyses will be performed for the whole cohort and also separately for Arms A and B. Differential treatment outcomes for patient subgroups may be explored using appropriate tests for interactions.
Time frame: Baseline
Frequency of Patients With Functional Impairment of DNA Damage Response Via Assessment With RAD51 Assay
Will be reported with exact binomial 95% confidence intervals. The association response will be described with appropriate tests for continuously measured biomarkers (t tests, Wilcoxon rank sum tests) and categorical biomarkers (Fisher's exact test). Descriptive analyses will be performed for the whole cohort and also separately for Arms A and B. Differential treatment outcomes for patient subgroups may be explored using appropriate tests for interactions.
Time frame: Baseline
Topotecan-induced Stabilization of Topoisomerase I-DNA Covalent Complexes
Topotecan-induced stabilization of topoisomerase I-DNA covalent complexes from peripheral blood
Time frame: Up to 7 months
Pharmacokinetic Sampling Studies Measured Using a Validated Liquid Chromatography/Tandem Mass Spectrometric Method in Plasma and Bone Marrow
Plasma trough levels will be obtained weekly through the first cycle to provide a steady-state assessment. Steady-state plasma concentrations will be calculated for each patient. Exploratory correlative studies between veliparib exposure (plasma and bone marrow) with pharmacodynamic (biological endpoints, toxicity and efficacy) will be analyzed using nonparametric statistics. Significance for comparisons will be at the p \< 0.05 level.
Time frame: Pre-treatment, day 1, day 8, day 14, day 15, and day 22 (approximately 24 hours post last dose)
| Milestone | Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin) | Arm B (Topotecan Hydrochloride, Carboplatin) |
|---|---|---|
| Started | 16 | 9 |
| Completed | 16 | 9 |
| Not completed | 0 | 0 |
Based on published standards for acute leukemias, Complete Response (CR) means less than 5% leukemic blasts in the bone marrow, no blasts in the blood, no longer presence of cytogenetic abnormalities, no longer presence of extramedullary disease, with or without absolute neutrophil count or platelet count recovery; Partial Remission (PR) includes the criteria for Complete Remission except there are 5-25% leukemic blasts in the bone marrow and there is absolute neutrophil count and platelet count recovery; Hematologic Improvement (HI) means the disease has not gotten worse and there is at least a 20% decrease in the leukemic blasts in the bone marrow and/or a decrease in leukemia symptoms. Response = CR, PR, or HI.
| Participants | Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin) | Arm B (Topotecan Hydrochloride, Carboplatin) |
|---|---|---|
| Participants with a response | 5 | 4 |
| Participants who did not have a response | 11 | 5 |
Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.
| Participants | Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin) | Arm B (Topotecan Hydrochloride, Carboplatin) |
|---|---|---|
| Grade 5 Adverse Events | 0 | 1 |
| Grade 4 Adverse Events | 14 | 8 |
| Grade 3 Adverse Events | 2 | 0 |
Study completion was either death or completion of all protocol-specified activities, whichever came first. Participants who came off study due to disease-related death were counted as having disease.
| Participants | Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin) | Arm B (Topotecan Hydrochloride, Carboplatin) |
|---|---|---|
| Number of Participants Without Disease at Study Completion | 3 | 3 |
Disease-free survival is defined as participants who are still alive and without disease at study completion. Study completion was either death or completion of all protocol-specified activities, whichever came first.
| days | Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin) | Arm B (Topotecan Hydrochloride, Carboplatin) |
|---|---|---|
| Duration of Disease-free Survival | 120 (37 to 137) | 89 (27 to 137) |
Study completion was either death or completion of all protocol-specified activities, whichever came first.
| Participants | Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin) | Arm B (Topotecan Hydrochloride, Carboplatin) |
|---|---|---|
| Number of Participants Still Alive at Study Completion | 5 | 5 |
Study completion was either death or completion of all protocol-specified activities, whichever came first. Duration was measured from the date of registration to the participant's study completion date.
| Days | Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin) | Arm B (Topotecan Hydrochloride, Carboplatin) |
|---|---|---|
| Duration of Overall Survival at the Time of Study Completion | 83 (74 to 295) | 123 (82 to 295) |
Minimal residual disease (MRD) refers to a small number of leukemic cells that remain after treatment.
No measurements were reported for this outcome.
Will be summarized using descriptive statistics. The association response will be described with appropriate tests for continuously measured biomarkers (t tests, Wilcoxon rank sum tests) and categorical biomarkers (Fisher's exact test). Descriptive analyses will be performed for the whole cohort and also separately for Arms A and B. Differential treatment outcomes for patient subgroups may be explored using appropriate tests for interactions.
No measurements were reported for this outcome.
Will be reported with exact binomial 95% confidence intervals. The association response will be described with appropriate tests for continuously measured biomarkers (t tests, Wilcoxon rank sum tests) and categorical biomarkers (Fisher's exact test). Descriptive analyses will be performed for the whole cohort and also separately for Arms A and B. Differential treatment outcomes for patient subgroups may be explored using appropriate tests for interactions.
No measurements were reported for this outcome.
Topotecan-induced stabilization of topoisomerase I-DNA covalent complexes from peripheral blood
No measurements were reported for this outcome.
Plasma trough levels will be obtained weekly through the first cycle to provide a steady-state assessment. Steady-state plasma concentrations will be calculated for each patient. Exploratory correlative studies between veliparib exposure (plasma and bone marrow) with pharmacodynamic (biological endpoints, toxicity and efficacy) will be analyzed using nonparametric statistics. Significance for comparisons will be at the p \< 0.05 level.
Results for this outcome have not been posted.
Collected over Up 7 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin) | 11/16 (68.8%) | 4/16 (25%) | 16/16 (100%) |
| Arm B (Topotecan Hydrochloride, Carboplatin) | 4/9 (44.4%) | 4/9 (44.4%) | 9/9 (100%) |
| Event | Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin) | Arm B (Topotecan Hydrochloride, Carboplatin) |
|---|---|---|
| SepsisInfections and infestations | 2/16 | 1/9 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/16 | 1/9 |
| FeverGeneral disorders | 0/16 | 1/9 |
| Skin infectionInfections and infestations | 0/16 | 1/9 |
| White blood cell count increasedInvestigations | 0/16 | 1/9 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 0/16 | 1/9 |
| HypotensionVascular disorders | 0/16 | 1/9 |
| Atrial fibrillationCardiac disorders | 1/16 | 0/9 |
| Lung infectionInfections and infestations | 1/16 | 0/9 |
| SinusitisInfections and infestations | 1/16 | 0/9 |
| Event | Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin) | Arm B (Topotecan Hydrochloride, Carboplatin) |
|---|---|---|
| AnemiaBlood and lymphatic system disorders | 14/16 | 9/9 |
| DiarrheaGastrointestinal disorders | 13/16 | 9/9 |
| Lymphocyte count decreasedInvestigations | 16/16 | 8/9 |
| White blood cell decreasedInvestigations | 16/16 | 9/9 |
| Platelet count decreasedInvestigations | 15/16 | 8/9 |
| HypoalbuminemiaMetabolism and nutrition disorders | 15/16 | 7/9 |
| HypokalemiaMetabolism and nutrition disorders | 15/16 | 5/9 |
| Neutrophil count decreasedInvestigations | 14/16 | 7/9 |
| NauseaGastrointestinal disorders | 10/16 | 7/9 |
| FatigueGeneral disorders | 8/16 | 7/9 |
| Age, Categorical(Participants) | Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin) | Arm B (Topotecan Hydrochloride, Carboplatin) | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 8 | 4 | 12 |
| >=65 years | 8 | 5 | 13 |
| Age, Continuous(years) | Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin) | Arm B (Topotecan Hydrochloride, Carboplatin) | Total |
|---|---|---|---|
| Median | 65 (33 to 75) | 69 (46 to 74) | 66 (33 to 75) |
| Sex: Female, Male(Participants) | Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin) | Arm B (Topotecan Hydrochloride, Carboplatin) | Total |
|---|---|---|---|
| Female | 4 | 1 | 5 |
| Male | 12 | 8 | 20 |
| Ethnicity (NIH/OMB)(Participants) | Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin) | Arm B (Topotecan Hydrochloride, Carboplatin) | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 16 | 8 | 24 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin) | Arm B (Topotecan Hydrochloride, Carboplatin) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 2 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 4 | 0 | 4 |
| White | 10 | 7 | 17 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin) | Arm B (Topotecan Hydrochloride, Carboplatin) | Total |
|---|---|---|---|
| United States | 16 | 9 | 25 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2018 to primary completion in May 2023, 56 months.
Results were first posted in Apr 2024, 10 months after primary completion.
Of 385 non-industry phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 108. This study's 56 months is below that.
Counting every sponsor, half of 442 studies reached it within 60 months; a quarter within 38 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Veliparib
National Cancer Institute (NCI) →